康泰生物(300601) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥816,136,339.32, an increase of 11.21% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥185,759,262.79, a decrease of 0.46% year-on-year, but a 66.94% increase quarter-on-quarter[3]. - The net profit for the first three quarters of 2024 was ¥351,095,608.08, representing a decline of 49.63% compared to the same period last year[2]. - The basic earnings per share for Q3 2024 was ¥0.16, down 5.88% from the previous year[2]. - Total operating revenue for the current period is CNY 2,018,201,664.48, a decrease of 18.06% compared to CNY 2,464,464,778.62 in the previous period[18]. - Net profit for the current period is CNY 351,075,774.02, a decline of 49.6% compared to CNY 697,050,864.48 in the previous period[19]. - The company reported a basic and diluted earnings per share of CNY 0.31, down from CNY 0.62 in the previous period[20]. Cash Flow and Liquidity - The company's cash flow from operating activities for the first three quarters was ¥236,205,250.86, down 62.25% year-on-year[2]. - Net cash flow from operating activities decreased by 62.25% to ¥236,205,250.86, due to reduced sales collections and increased raw material purchases[10]. - The company reported a net decrease in cash and cash equivalents of ¥998,247,579.40, a significant decline of 6995.64% compared to the previous year[10]. - The company's cash and cash equivalents decreased to CNY 190,632,300.70 from CNY 1,195,582,446.07, indicating a significant reduction in liquidity[15]. - Cash inflow from operating activities totaled CNY 2,027,717,804.92, compared to CNY 2,300,307,228.26 in the previous period, reflecting a decrease of 11.8%[21]. - The total cash and cash equivalents at the end of the period were 172,078,219.70 CNY, down from 1,008,585,794.05 CNY at the end of the previous year[22]. - The company reported a total cash outflow of 1,791,512,554.06 CNY from operating activities, compared to 1,674,535,201.33 CNY in the previous year[22]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥14,515,539,714.49, a decrease of 3.78% from the end of the previous year[2]. - As of September 30, 2024, the total assets of Shenzhen Kangtai Biological Products Co., Ltd. amounted to CNY 14,515,539,714.49, a decrease from CNY 15,085,358,535.27 at the beginning of the period[15]. - The company's total liabilities decreased to CNY 8,664,915,448.75 from CNY 9,689,354,681.20, indicating a reduction of about 10.6%[16]. - The total current liabilities increased to CNY 1,488,856,324.15 from CNY 1,645,656,417.71, showing a decrease of approximately 9.6%[16]. - The company’s total liabilities decreased to CNY 4,806,051,505.11 from CNY 5,543,673,229.15, a reduction of 13.3%[19]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 65,682, with the top ten shareholders holding significant stakes[11]. - The largest shareholder, Du Weimin, holds 25.50% of shares, totaling 284,775,143 shares[11]. - The company reported a decrease in restricted shares from 241,737,629 to 235,537,028, a reduction of about 2.5%[14]. Expenses and Investments - Management expenses increased by 42.76% to ¥244,620,221.51 due to higher depreciation expenses from asset capitalization[9]. - Financial expenses rose significantly by 1067.12% to ¥18,294,027.92, primarily due to a decrease in interest income[9]. - Other income decreased by 48.20% to ¥61,279,404.53, attributed to lower government subsidies received[9]. - Investment income fell by 71.63% to ¥481,740.54, resulting from reduced returns on bank wealth management products[9]. - Research and development expenses for the current period were CNY 311,770,025.07, a decrease of 13.0% from CNY 358,500,265.94 in the previous period[19]. - Sales expenses decreased to CNY 671,404,158.08, down 20.6% from CNY 845,517,600.10 in the previous period[19]. Borrowings and Financing Activities - The company's short-term borrowings increased by 159.28% to ¥155,678,905.79 due to new borrowings during the period[8]. - The company paid 611,535,953.51 CNY in debt repayment, significantly higher than 132,131,074.14 CNY in the same quarter last year[22]. - Net cash flow from financing activities decreased by 193.91% to -¥676,404,914.41, primarily due to bank loan repayments and cash dividend distributions[10]. Other Information - The company received government subsidies amounting to ¥61,761,069.23 for the year-to-date, contributing positively to the financial results[4]. - The company did not undergo an audit for the third quarter report[23]. - The company has not adopted the new accounting standards for the current year[23].